Literature DB >> 6694168

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent.

M F Stevens, J A Hickman, R Stone, N W Gibson, G U Baig, E Lunt, C G Newton.   

Abstract

Interaction of 5-diazoimidazole-4-carboxamide and alkyl and aryl isocyanates in the dark affords 8-carbamoyl-3-substituted-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-on es. In cold methanol or ethanol, the 3-(2-chloroethyl) derivative 7a decomposes to afford 2-azahypoxanthine (14) and methyl and ethyl N-(2-chloroethyl)carbamates, respectively. Compound 7a has curative activity against L-1210 and P388 leukemia and may act as a prodrug modification of the acyclic triazene 5-[3-(2-chloroethyl)triazen-1-yl]imidazole-4-carboxamide (MCTIC), since it ring opens to form the triazene in aqueous sodium carbonate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6694168     DOI: 10.1021/jm00368a016

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  47 in total

1.  Phase I study of mitozolomide on a once daily for 5 days schedule.

Authors:  J H Schornagel; G Simonetti; R Dubbelman; W W ten Bokkel Huinink; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers.

Authors:  Annette Nørregaard; Stine Skov Jensen; Jesper Kolenda; Charlotte Aaberg-Jessen; Karina Garnier Christensen; Poul Henning Jensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  Neurotox Res       Date:  2011-12-28       Impact factor: 3.911

3.  Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner.

Authors:  Silvia Würstle; Fabian Schneider; Florian Ringel; Jens Gempt; Friederike Lämmer; Claire Delbridge; Wei Wu; Jürgen Schlegel
Journal:  Oncol Lett       Date:  2017-05-02       Impact factor: 2.967

4.  Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.

Authors:  L L Tsang; P B Farmer; A Gescher; J A Slack
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Phase II study of mitozolomide (M & B 39,565) in head and neck cancer.

Authors:  P Herait; J P Armand; M Benahmed; C Domenge; X Fontana; G Recondo; E Cvitkovic; F M Delgado
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

6.  Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.

Authors:  C Dive; P Workman; J V Watson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  An efficient and practical radiosynthesis of [11C]temozolomide.

Authors:  Christian K Moseley; Stephen M Carlin; Ramesh Neelamegam; Jacob M Hooker
Journal:  Org Lett       Date:  2012-11-14       Impact factor: 6.005

Review 8.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.

Authors:  Jinming Yang; Snjezana Zaja-Milatovic; Yee-Mon Thu; Francis Lee; Richard Smykla; Ann Richmond
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

10.  In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma.

Authors:  M Broggini; E Erba; L Morasca; C Horgan; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.